AbstractIn this work, a novel three nitro‐group‐bearing monomer 3,6‐dinitro‐9‐(2‐trifluoromethyl‐4‐nitrophenyl)‐carbazole (Car‐3NO2‐CF3) via a CN coupling reaction between 3,6‐dinitro‐9H‐carbazole (Car‐2NO2) and 2‐chloro‐5‐nitrobenzotrifluoride is synthesized, and obtained single crystal and single crystal analysis data for this compound. The crystal system of Car‐3NO2‐CF3 is monoclinic and it has a P 21/c space group. This new monomer (Car‐3NO2‐CF3) is also utilized to synthesize a novel azo‐linked polymer (Azo‐Car‐CF3). The trifluoromethyl group has polar CF bonds, and thus it is an effective functional group for the capture of iodine. Azo‐Car‐CF3 has great thermal stability with a mass loss of only 10% at 414 °C, as well as good chemical stability as is demonstrated by its low solubility in common organic solvents such as tetrahydrofuran (THF), acetone, methanol, ethanol, and N,N‐dimethylformamide (DMF). The specific surface area of Azo‐Car‐CF3 can reach as high as 335 m2 g−1. Azo‐Car‐CF3 exhibits an excellent capacity for iodine adsorption and can reach up to 1198 mg g−1 in cyclohexane solution, and its adsorption capacity for iodine vapor can get to 2100 mg g−1. In addition, ethanol can be used to trigger the release of the captured iodine to be easily released from Azo‐Car‐CF3.

01 Feb 1991·Tumori JournalQ4 · MEDICINE

Comparison of Two Newly Identified Tumor Markers (CAR-3 AND DU-PAN-2) with CA 19-9 in Patients with Pancreatic Cancer

Q4 · MEDICINE

Article

Author: Meggiato, Tamara ; Ferrara, Chiara ; Scalon, Paola ; Panozzo, Maria P. ; Plebani, Mario ; Malesci, Alberto ; Naccarato, Remo ; Burlina, Angelo ; Fogar, Paola ; Basso, Daniela ; Del Favero, Giuseppe ; Fabris, Carlo ; Di Mario, Francesco

We compared the diagnostic utility of DU-PAN-2 and CAR-3 with that of CA 19-9 in differentiating pancreatic cancer (23 patients) from chronic pancreatitis (16 patients) and various extra-pancreatic diseases (28 patients) mainly of the upper gastrointestinal and biliary tract. The influence of some pathophysiologic variables on the three markers was also assessed. The sensitivities of the three markers in detecting pancreatic cancer were: CA 19-9, 83%; DU-PAN-2, 56%; and CAR-3, 39%. In patients with chronic pancreatitis and extra-pancreatic diseases, CA 19-9 gave the highest number of false positives. Receiver-operating characteristic curves showed that the ability of CAR-3 to discriminate between pancreatic cancer and other diseases was similar to that of CA 19-9, whereas DU-PAN-2 was a less reliable discriminator. Correlations were found between the behavior of all three markers and that of the cholestasis indices (ALP and GGT). Our findings indicate that DU-PAN-2 and CAR-3 serum determinations do not provide any more information than does CA 19-9 alone. The latter remains the marker of choice in the differential diagnosis of pancreatic cancer, even though it cannot be considered a definitive aid. Serum levels of all three markers increase in the presence of extrahepatic cholestasis, possibly due to interference with the hepatic clearance of glycoproteins and destruction of ductal biliary epithelium.

100 Deals associated with CAR-003

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Genetic Diseases, Inborn	Preclinical	United States	CaraVan Biologix, Inc.	01 Feb 2025
Lymphohistiocytosis, Hemophagocytic	Preclinical	United States	CaraVan Biologix, Inc.	16 Apr 2024

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

CAR-003

Overview

Basic Info

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation